Neurelis, Inc., a San Diego, CA-based specialty pharmaceutical company organized to license, develop, and commercialize product candidates for epilepsy and the broader central nervous system (CNS) market, closed a Series B financing round of undisclosed amount.
The round was led by HBM Healthcare Investments with participation from Lyzz Capital.
The company will use the funds to complete clinical trials for NRL-1 (intranasal diazepam), prepare the planned New Drug Application (NDA) for submission to the U.S. Food and Drug Administration (FDA), and begin preparations for the commercial launch of the product.
NRL-1 is being developed for pediatric, adolescent, and adult epilepsy patients who experience acute repetitive or cluster seizures. The program is in the final phase of clinical development and the NDA application is planned for submission in 2018.
Led by Craig C. Chambliss, President and Chief Executive Officer, Neurelis licenses, develops, and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market.